Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM90EO3)

Drug Name

ABBV-621 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Haematological malignancy	2B33.Y	Phase 1	[1]
Hematologic tumour	2B33.Y	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TNF related apoptosis inducing ligand (TNFSF10)	TTA5MS9	TNF10_HUMAN	Agonist	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
TNF related apoptosis inducing ligand (TNFSF10)	DTT	TNFSF10	5.928	7.18	8.754	8.143

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Haematological malignancy

ICD Disease Classification

2B33.Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
TNF related apoptosis inducing ligand (TNFSF10)	DTT	TNFSF10	4.40E-01	-0.16	-0.18

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT03082209) A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of AbbVie.